Patients should be within 7 day window for mAb therapy and within 5 day window for oral therapy.

All individuals should be within 7 days of sx. onset and have mild/mod disease (spO2 > 92%) regardless of other criteria. No patient > 7 days from sx onset should receive therapy. Patients who got Evusheld do NOT qualify for mAb therapy.

High risk patients who are within the 7 day window qualify for therapy:

- Recipients of a solid organ transplant
- Rheumatologic and derm patients on immunosuppressive drugs (DMARDS, biologics, and >/= 20mg prednisone/day)
- Patients with/undergoing stem cell transplant
- Patients with HIV (especially with CD4 counts </=200 or <15% CD4)
- Those with primary immunodeficiency (Common Variable Immunodeficiency, Hypogamma, etc)
- Other patients deemed immunosuppressed by provider who are also found to be non-responders (lab evidence of non-reactive anti-spike protein antibody > 14 days from booster or completed vaccine series)
- Adults who are NOT completely vaccinated - patients are considered vaccinated if they have had the booster, OR completed the Pfizer/Moderna vaccine in the last 5 mths OR the J&J within the last 2 mths.
- Age ≥ 55 OR BMI ≥30 OR Diabetes OR Chronic lung, heart, liver, or kidney disease
- Neurologic disease including Parkinsons, dementia, MS, spinal cord disease.
- Hematologic diseases such as sickle cell or cytopenias OR any active malignancy (cancer)

ORAL THERAPIES ONLY AVAILABLE IN SELECT PHARMACIES. In order to prescribe therapy you may:

- Access the EHR and prescribe mAb or orals using Covid Outpatient Antiviral Therapy order set. No restrictions.
  - ECU Pharmacy/ Moye Blvd typically has oral meds. Or check [https://covid19.ncdhhs.gov/FindTreatment](https://covid19.ncdhhs.gov/FindTreatment)
- Consult Covid Virtual Clinic with the EHR using AMB REFERRAL TO COVID VIRTUAL CLINIC or call 252-830-2021
- Any person (patient or provider) can call the hotline (252 847-6500) M-F 8am-4pm. If needed the hotline can route patients to the Covid Virtual Clinic for oral treatment.

--- Treatment Options ---


**Option #2 - Sotrovimab or Bebtelovimab** - Only available under EUA in 7 day window. Monoclonal Antibody infusion. If patient unwilling/unable, or antibody not available, consider other options.

**Option #3 - Lagevrio (molnupiravir)** - Only available under EUA. 5 day window from sx onset. 4 capsules twice a day for 5 days. Probably less efficacious. Works by inducing errors in DNA transcription and is therefore mutagenic/teratogenic. Requires (-) pregnancy test in women of childbearing age. Cannot use in patients < age 18. Few drug interactions. Limited supply in certain community pharmacies and ECU Health.

**Option #4 Luvox (fluvoxamine)** - FDA approved for depression but off label for covid. 100mg po bid x 10 days. Off label use though studies suggest may reduce need for hospitalization. NIH currently states “insufficient evidence to recommend either for or against use”

For all other patients within the 5 day window with mild/mod disease who, per clinician's judgment, are at high risk for progression to severe COVID-19, provider may consider therapy with Paxlovid, molnupiravir or fluvoxamine.